Latest Conference Articles

December 15th 2025, 7:40pm

San Antonio Breast Cancer Symposium

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

December 15th 2025, 2:00pm

ASH Annual Meeting and Exposition

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

December 15th 2025, 1:00pm

ASH Annual Meeting and Exposition

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

December 14th 2025, 11:00am

ASH Annual Meeting and Exposition

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

December 14th 2025, 11:00am

ASH Annual Meeting and Exposition

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

December 12th 2025, 11:00pm

San Antonio Breast Cancer Symposium

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

December 12th 2025, 10:48pm

San Antonio Breast Cancer Symposium

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

December 12th 2025, 10:06pm

San Antonio Breast Cancer Symposium

Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.

December 12th 2025, 9:30pm

San Antonio Breast Cancer Symposium

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

December 12th 2025, 7:05pm

San Antonio Breast Cancer Symposium

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

December 12th 2025, 6:06pm

San Antonio Breast Cancer Symposium

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

December 12th 2025, 5:26pm

San Antonio Breast Cancer Symposium

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

December 12th 2025, 5:12pm

ASH Annual Meeting and Exposition

TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.

December 12th 2025, 3:12pm

San Antonio Breast Cancer Symposium

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

December 12th 2025, 2:35pm

San Antonio Breast Cancer Symposium

December 12th 2025, 1:41pm

ASH Annual Meeting and Exposition

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

December 12th 2025, 3:04am

San Antonio Breast Cancer Symposium

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

December 12th 2025, 1:43am

San Antonio Breast Cancer Symposium

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

December 12th 2025, 12:28am

San Antonio Breast Cancer Symposium

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

December 12th 2025, 12:16am

San Antonio Breast Cancer Symposium

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.